Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda and Actimmune in Mycosis Fungoides, Sezary Syndrome, and Synovial Sarcoma
NCT03063632Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Dec 2017
- Primary completion
- Apr 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in mycosis fungoides (MF), Sézary syndrome (SS), synovial sarcoma (SS), myxoid liposarcoma (MLPS), myxoid/round cell liposarcoma (MRCLS), sponsored by National Cancer Institute. Started Dec 2017; status: completed.
02
Drugs
03
Conditions
mycosis fungoides (MF)Sézary syndrome (SS)synovial sarcoma (SS)myxoid liposarcoma (MLPS)myxoid/round cell liposarcoma (MRCLS)
Beyond the preview
Go deeper on NCT03063632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03063632.